Descripción de la empresa
VYNE Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise dedicated to developing therapeutic interventions for chronic inflammatory and immune-mediated conditions. The company functions within the Healthcare sector, specifically under the Biotechnology industry, which implies a focus on research and development phases prior to widespread commercialization. This biopharmaceutical entity maintains a market capitalization of $19.76M, generates annual revenue of $570,000, and employs a workforce of 10 individuals. The combination of a market cap under $20 million and revenue in the low six figures indicates that the company is a micro-cap entity with limited operational scale, characteristic of early-stage firms where capital allocation is heavily weighted toward advancing lead programs such as repibresib gel (VYN201) rather than expansive commercial distribution networks.
Salud financiera
The company reported revenue of $570,000 over the trailing twelve months, yet incurred a net income of $-26,736,000 and an EBITDA of $-29,726,000, revealing a cost structure dominated by significant operational expenses that far exceed current sales generation. Free cash flow stands at $-26,668,124, indicating that the company is currently consuming cash reserves to fund its development activities rather than generating surplus liquidity from operations. The gross margin is recorded at 100.0%, which is typical for pre-revenue or low-revenue biotechnology firms with minimal cost of goods sold relative to sales, while the operating margin of -4014.6% and profit margin of 0.0% highlight the substantial overhead costs inherent in clinical-stage development. The firm holds $29.01M in cash with no debt listed, as the debt field is N/A, suggesting a highly conservative balance sheet that is not leveraged and provides a substantial buffer against burn rates. The current ratio is 12.53, a metric that signifies extremely strong short-term liquidity, as the company possesses more than twelve times the current assets necessary to cover its immediate liabilities. Furthermore, the return on equity is -67.0% and the return on assets is -38.3%, metrics that reveal management is currently generating negative returns on capital as the company prioritizes long-term asset accumulation and clinical progression over short-term profitability.
Evaluación de valoración
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -0.36, a figure that implies the market expects earnings to remain negative in the near term before turning positive. The price-to-book ratio is 0.71, indicating that the market is currently valuing the company at a discount to its net asset book value, which often occurs with speculative biotechnology assets that lack immediate earnings power. Alternative valuation metrics such as a price-to-sales ratio of 34.67 and an EV/EBITDA of 0.31 suggest that investors are pricing the firm based on potential future value rather than current cash flows or earnings multiples. The stock has traded within a 52-week range bounded by a high of $1.99 and a low of $0.28, meaning the current price sits significantly below the 52-week high while remaining well above the recent lows. The beta value is 1.95, which indicates that the stock price volatility is substantially higher than the broader market, reflecting the high risk and sensitivity associated with clinical-stage biotechnology equities.
Growth & Income
Revenue growth year-over-year is recorded at 54.8%, whereas earnings growth is N/A, implying that top-line expansion is occurring while the company continues to operate at a loss, a common dynamic in the biotechnology sector during clinical trial phases. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are theoretically reinvested into growth initiatives rather than distributed to shareholders. The absence of a dividend yield confirms that the company's financial strategy focuses on retaining capital for research and development rather than providing income to investors. Overall, the growth and income profile is characterized by rapid revenue expansion supported by a robust cash position, with no current distribution of income to compensate for the lack of profitability.